Submission of Outcome of the Board Meeting held on 14th August, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals' Board approved unaudited Q1 FY26 results showing revenue from operations of Rs. 2,235.12 lakhs, a sharp jump from just Rs. 50.11 lakhs in Q1 FY25, driven entirely by its Pharma (API/Bulk Drugs) segment. The company swung to a profit of Rs. 10.70 lakhs (EPS Rs. 0.09) versus a loss of Rs. 35.35 lakhs in the year-ago quarter. Auditor CVS Balachandra Rao & Co. issued a clean limited review report with no qualifications. The Board also approved allotment of 15.45 lakh equity shares on conversion of warrants at Rs. 20 each (raising Rs. 2.32 crore), taking paid-up capital from Rs. 12.94 crore to Rs. 14.48 crore. Two new directors were appointed, and the 31st AGM is set for 19th September 2025. Additionally, the Board recommended special resolutions to raise borrowing and investment/guarantee limits up to Rs. 500 crore each.
Strong quarter-on-quarter revenue surge and return to profitability signal a genuine business turnaround in the core pharma segment after a near-dormant Q1 FY25. The proposed Rs. 500 crore borrowing and investment limits suggest future expansion or acquisitions, which could dilute equity or increase leverage if actually utilised. Warrant conversion is mildly dilutive but reinforces promoter confidence.